For Connecticut’s cannabis entrepreneurs, the buzz surrounding the potential federal move to reclassify marijuana from Schedule I to Schedule III is palpable. It is being hailed as a historic milestone, but if you talk to those on the ground—the business owners, policy experts, and dispensary managers—the mood is less of a victory lap and more of a cautious “wait and see.” While the industry is hungry for change, the road to federal rescheduling is looking more like a slow, complicated shuffle than a swift legislative sprint.
The primary hope for the industry lies in finally addressing the massive tax burden created by Section 280E of the federal tax code. Because cannabis is currently classified as a Schedule I substance, businesses are prohibited from deducting ordinary expenses, which forces them to pay taxes on gross revenue and pushes effective tax rates as high as 70%. For local operators like Budr, moving to Schedule III would essentially eliminate this hurdle, potentially boosting their bottom lines by 12–14%. That is capital that could be immediately funneled back into hiring, store improvements, and expansion.
However, anyone expecting immediate change should temper their expectations. The move toward rescheduling is not as simple as flipping a switch; it is a rigorous administrative process that involves formal hearings before federal judges and is almost certain to be met with litigation from groups opposed to the change. Analysts are looking at a timeline that could easily stretch deep into 2026 or 2027, leaving businesses to navigate a long period of uncertainty.
Beyond the wait, there is a legitimate concern that rescheduling could trade old problems for new ones. Bringing cannabis under the oversight of the FDA could lead to strict, costly requirements similar to those faced by pharmaceutical companies, including mandatory clinical trials. There is also a pervasive fear that federal rules might eventually require cannabis to be dispensed exclusively through DEA-registered pharmacies. Since Connecticut’s medical dispensaries are not structured as traditional pharmacies, many are worried they could find themselves in a legal purgatory where they no longer fit the old regulatory framework but are unable to comply with the new federal one.
It is crucial to remember that rescheduling is not the same as full federal legalization. The fundamental friction between state-legal markets and federal law remains, meaning that persistent issues regarding banking, insurance, and interstate commerce are unlikely to vanish overnight. While the Connecticut Cannabis Chamber of Commerce views this as a vital first move in correcting decades of punitive policy, the industry consensus remains that rescheduling is merely a patch rather than a total cure. For now, Connecticut’s cannabis entrepreneurs are moving forward with a sense of hopeful but guarded pragmatism, knowing that the real work of aligning federal law with the reality of the states is only just beginning.
Dabbin-Dad Newsroom
